日前，加州大学洛杉矶分校的研究人员在《Blood》上报告了实验性基因疗法治疗重症联合免疫缺陷（ADA-SCID）儿童的相关数据，结果显示，在2009-2012年期间接受该疗法的儿童中，90%截至目前尚未出现疾病进展。 重症联合免疫缺陷（ADA-SCID）是一种罕见且危及生命的 ...

为解决艾拉培加德酶（elapegademase）在腺苷脱氨酶严重联合免疫缺陷（ADA-SCID）患者中的安全性和有效性数据有限的问题，研究人员开展了一项多中心注册研究。结果显示，该药在长达 4 年的使用中效果良好且无新安全问题，对患者治疗意义重大。 在人体的生命 ...

ADA-SCID is an ultra-rare, inherited genetic disorder, caused by a deficiency in the ADA enzyme that is fatal if left untreated. Patients affected by ADA-SCID have compromised immune systems that ...

A blood stem cell gene therapy co-developed by UCLA’s Dr. Donald Kohn restored immune function in 59 of 62 children with ADA-SCID, a rare and fatal immune disorder, with no serious complications ...

十多年前，加州大学洛杉矶分校（UCLA）的科学家开始使用他们设计的开创性基因疗法来治疗出生时患有一种罕见且致命的免疫系统疾病——腺苷脱氨酶缺乏症引起的重症联合免疫缺陷（ADA-SCID）——的儿童。 2021年10月14日，研究团队在《血液》（Blood）上发文 ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Leadiant Biosciences, Inc. today announced that the Food and Drug Administration (FDA) has granted approval to Revcovi™ (elapegademase-lvlr) injection in the U.S.

During the sixth month of PEG-ADA discontinuation, with the patient in good clinical status, a routine examination of the fundus revealed papilledema associated with increased intracranial pressure.

“I remember asking the doctor if my daughter was going to die,” said Chelsea Oakley, mother of Cora Oakley, a newborn who was diagnosed with ADA-SCID when she was just seven days old, in April 2017.

Following a positive opinion from the EMA, the transfer of marketing authorization of Strimvelis from Orchard Therapeutics has been approved by the European Commission Fondazione Telethon will now be ...

For decades, scientists have been trying to find ways to cure disorders that can be traced back to an error in one gene. One of the first diseases that researchers ...

Adenosine deaminase (ADA) deficiency leads to build up of toxic metabolites that causes severe combined immunodeficiency (SCID) and a systemic metabolic defect. ADA–SCID is an ultra-rare condition ...

BOSTON and LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data published in the New England Journal of Medicine (NEJM) ...